A Study of a New Surgical Treatment of Macular Hole Retinal Detachment in High Myopia

Inclusion Criteria: 1. Prior written informed consent should be obtained before any assessment is carried out; 2. Participants are more than 18 years of age, and less than 75 years of age, male or female Chinese patients; 3. Visual impairment is caused by macular hole associated with retinal detachment secondary to high myopia; 4. Axial length ≥ 26mm, or the refractive error ≥ -6.0D Exclusion Criteria: 1. Failure to comply with research or follow-up procedures; 2. Diabetes with uncontrolled blood glucose (defined as fasting plasma glucose more than 7.0mmol/L or blood glucose more than 11.1mmol/ L 2 hours postprandial), and / or with diabetic retinopathy; 3. Poor control of blood pressure in hypertensive patients (defined as blood pressure \>150/95mmHg, including antihypertensive medication); 4. With surgical contraindication due to other local or systemic conditions at screening or baseline; 5. With any active ocular or periocular infection or inflammation (e.g., blepharitis, conjunctivitis, keratitis, scleritis, uveitis, endophthalmitis) at screening or baseline; 6. With uncontrolled glaucoma at screening or baseline (IOP ≥ 30mmHg when receiving medical treatment or as judged by the researchers); 7. With the presence of iris neovascularization or neovascular glaucoma at screening or baseline; 8. With ocular diseases which may interfere the study results at screening or baseline , including severe vitreous hemorrhage, peripheral retinal hole, proliferative diabetic retinopathy, proliferative vitreoretinopathy ( ≥ Level C ), choroidal detachment; 9. With other causes which may result in macular hole associated-retinal detachment at screening or baseline,except high myopia; 10. Previously underwent scleral buckling surgery; 11. With current or planned medication known to have toxic effects on the lens, retina or optic nerve, including hydroxychloroquine, chloroquine, hydroxychloroquine, tamoxifen, phenothiazine and ethambutol; 12. With laboratory abnormalities, such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TB), gamma-glutamyl transferase (GGT), lactate dehydrogenase (LDH), exceeded the normal limit by more than 2 times, and serum creatinine or blood urea nitrogen exceeded 1.2 times the normal limit; 13. With abnormal coagulation function (defined as more than normal prothrombin time for 3 seconds or more, more than 1.5 of the international standard ratio (INR), activated partial thromboplastin time of 10 seconds or longer than the upper limit of normal time); 14) Patients who participated in any clinical study of medication within 3 months prior to screening (excluding vitamins and minerals) Exit criteria: 1. Due to adverse events, especially severe adverse events, the researchers consider withdrawal of patients based on concerns of safety and ethics; 2. Drop out; 3. The patients voluntarily withdraw the informed consent; 4. Serious violation of the study protocol due to the subjects or investigators' reasons; 5. Other reasons that the researchers believe for quitting the study